L-TYROSINE

Date: March 17, 2008

Proper name(s): L-Tyrosine (NIH 2007; USP 30)

Common name(s): L-Tyrosine, tyr, tyrosine (NIH 2007; USP 30)

Source material(s): L-Tyrosine (USP 30)

Route(s) of administration: Oral

Dosage form(s): Those pharmaceutical dosage forms suited to oral administration, including but not limited to chewables (e.g. gummies, tablets), caplets, capsules, strips, lozenges, powders or liquids where the dose is measured in drops, teaspoons or tablespoons, are acceptable.
This monograph is not intended to include food-like dosage forms such as bars, chewing gums or beverages.

Use(s) or Purpose(s): Statement(s) to the effect of:

Helps to decrease cognitive fatigue due to physically stressful situations (e.g. extended wakefulness, exposure to cold, excessive noise) (Mahoney et al. 2007; O’Brien et al. 2006; Magill et al. 2003; Thomas et al. 1999; Dollins et al. 1995; Neri et al. 1995).

Dose(s): 10 g, 1-2 times per day (Mahoney et al. 2007; O’Brien et al. 2006; Magill et al. 2003; Thomas et al. 1999; Neri et al. 1995).

Directions for use: Take up to one hour before, or during periods of physical stress (Mahoney et al. 2007; O’Brien et al. 2006; Magill et al. 2003; Thomas et al. 1999; Neri et al. 1995).

Duration of use: For occasional use only.
Risk information: Statement(s) to the effect of:

Caution(s) and warning(s):
- Consult a health care practitioner prior to use if you are pregnant or breastfeeding.
- Consult a health care practitioner prior to use if you are following a low protein diet (Goldman and Ausiello 2004).

Contraindication(s): No statement required.

Known adverse reaction(s): No statement required.

Non-medicinal ingredients: Must be chosen from the current NHPD List of Acceptable Non-medicinal Ingredients and must meet the limitations outlined in the list.

Specifications:
- The finished product must comply with the minimum specifications outlined in the current NHPD Compendium of Monographs.
- The medicinal ingredient must be pharmacopoeial grade (for a list of acceptable pharmacopoeia, see the NHPD Evidence for Quality of Finished Natural Health Products Guidance Document) or cited in an approved NHP Master File, authorized by a letter of access issued to the applicant by the NHP Master File's registered owner.

References cited:

Dollins AB, Krock LP, Storm WF, Wurtman RJ, Lieberman HR L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiology and Behavior 1995;57(2):223-230


References reviewed:


